A Novel Paradigm for Adult-Onset Type 1 Diabetes: Once-Weekly Basal Insulin and SGLT-2 Inhibition to Harness Residual β-Cell Function

IF 8.3 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Paolo Pozzilli, Richard David Leslie
{"title":"A Novel Paradigm for Adult-Onset Type 1 Diabetes: Once-Weekly Basal Insulin and SGLT-2 Inhibition to Harness Residual β-Cell Function","authors":"Paolo Pozzilli,&nbsp;Richard David Leslie","doi":"10.1002/dmrr.70247","DOIUrl":null,"url":null,"abstract":"<p>Type 1 diabetes (T1D) in adults is characterised by a less aggressive disease course than in children. Most patients retain preserved C-peptide (&gt; 0<span></span><math>\n <semantics>\n <mrow>\n <mo>.</mo>\n </mrow>\n <annotation> $.$</annotation>\n </semantics></math>2 nmol/L) and some of them benefit from a protracted phase without the need for insulin. Here, we propose a hypothesis-generating therapeutic paradigm with once-weekly basal insulin combined with an SGLT2 inhibitor (SGLT2is) as initial therapy in T1D patients with preserved C-peptide. Once-weekly basal insulin, approved in Europe and now also in the US, confirm comparable HbA1c reductions to insulin degludec or glargine, albeit always alongside prandial insulin. SGLT2is, approved as adjuncts in T1D in select regions, can control prandial peaks without boluses. No trials have tested the combination of weekly insulin with SGLT2is in adult T1D patients. Nonetheless, the rationale is robust especially in adults with C-peptide &gt; 0·2 nmol/L. In this respect, we urge proof-of-concept trials of 12-months randomised studies in adults ≥ 18 years, to evaluate this combination.</p>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"42 7","pages":""},"PeriodicalIF":8.3000,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70247","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes/Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70247","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Type 1 diabetes (T1D) in adults is characterised by a less aggressive disease course than in children. Most patients retain preserved C-peptide (> 0 . $.$ 2 nmol/L) and some of them benefit from a protracted phase without the need for insulin. Here, we propose a hypothesis-generating therapeutic paradigm with once-weekly basal insulin combined with an SGLT2 inhibitor (SGLT2is) as initial therapy in T1D patients with preserved C-peptide. Once-weekly basal insulin, approved in Europe and now also in the US, confirm comparable HbA1c reductions to insulin degludec or glargine, albeit always alongside prandial insulin. SGLT2is, approved as adjuncts in T1D in select regions, can control prandial peaks without boluses. No trials have tested the combination of weekly insulin with SGLT2is in adult T1D patients. Nonetheless, the rationale is robust especially in adults with C-peptide > 0·2 nmol/L. In this respect, we urge proof-of-concept trials of 12-months randomised studies in adults ≥ 18 years, to evaluate this combination.

成人发病型1型糖尿病的新模式:每周一次的基础胰岛素和SGLT-2抑制来控制残余β细胞功能
成人1型糖尿病(T1D)的特点是病程的侵袭性低于儿童。大多数患者保留c肽(> 0)。美元。$ 2 nmol/L),其中一些受益于不需要胰岛素的延长阶段。在这里,我们提出了一种假设生成的治疗模式,即每周一次的基础胰岛素联合SGLT2抑制剂(SGLT2is)作为保存c肽的T1D患者的初始治疗。每周一次的基础胰岛素已在欧洲和美国获得批准,证实了与去糖精胰岛素或甘精胰岛素相当的HbA1c降低,尽管总是与膳食胰岛素同时使用。SGLT2is在特定地区被批准作为T1D的辅助药物,可以在不给药的情况下控制膳食高峰。成人T1D患者中,没有试验测试每周胰岛素与SGLT2is联合使用。尽管如此,其基本原理是强有力的,特别是在c肽为0.2 nmol/L的成年人中。在这方面,我们敦促在≥18岁的成年人中进行12个月的随机化研究的概念验证试验,以评估这种组合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes/Metabolism Research and Reviews
Diabetes/Metabolism Research and Reviews 医学-内分泌学与代谢
CiteScore
17.20
自引率
2.50%
发文量
84
审稿时长
4-8 weeks
期刊介绍: Diabetes/Metabolism Research and Reviews is a premier endocrinology and metabolism journal esteemed by clinicians and researchers alike. Encompassing a wide spectrum of topics including diabetes, endocrinology, metabolism, and obesity, the journal eagerly accepts submissions ranging from clinical studies to basic and translational research, as well as reviews exploring historical progress, controversial issues, and prominent opinions in the field. Join us in advancing knowledge and understanding in the realm of diabetes and metabolism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书